Efficacy and safety of oral fumarate in patients with relapsing-remitting multiple sclerosis: a multicentre, randomised, double-blind, placebo-controlled phase IIb study.
about
Neurodegeneration in multiple sclerosis: novel treatment strategiesNew and emerging disease modifying therapies for multiple sclerosisMultiple Sclerosis: Where Will We Be in 2020?Development of oral agent in the treatment of multiple sclerosis: how the first available oral therapy, Fingolimod will change therapeutic paradigm approachDimethyl fumarate for multiple sclerosisImmunomodulators and immunosuppressants for relapsing-remitting multiple sclerosis: a network meta-analysisDimethyl fumarate for multiple sclerosisOral ponesimod in relapsing-remitting multiple sclerosis: a randomised phase II trialIdentification of targets and new developments in the treatment of multiple sclerosis--focus on cladribineTriptolide in the treatment of psoriasis and other immune-mediated inflammatory diseasesThe Nrf2-antioxidant response element signaling pathway and its activation by oxidative stressDimethyl fumarate in multiple sclerosis: latest developments, evidence and place in therapyImpact of Exercise on Innate Immunity in Multiple Sclerosis Progression and SymptomatologyDimethyl fumarate in the management of multiple sclerosis: appropriate patient selection and special considerationsPharmacology and Clinical Drug Candidates in Redox MedicineOptimizing therapeutics in the management of patients with multiple sclerosis: a review of drug efficacy, dosing, and mechanisms of actionTreatment-related progressive multifocal leukoencephalopathy: current understanding and future stepsMultiple sclerosis-a quiet revolutionAnti-inflammatory dimethylfumarate: a potential new therapy for asthma?Regression to the mean and predictors of MRI disease activity in RRMS placebo cohorts--is there a place for baseline-to-treatment studies in MS?Design of oral agents for the management of multiple sclerosis: benefit and risk assessment for dimethyl fumarateMultiple sclerosis: molecular mechanisms and therapeutic opportunitiesPreferential uptake of antioxidant carbon nanoparticles by T lymphocytes for immunomodulation.The Berlin Treatment Algorithm: recommendations for tailored innovative therapeutic strategies for multiple sclerosis-related fatigueUtilization of Dimethyl Fumarate and Related Molecules for Treatment of Multiple Sclerosis, Cancer, and Other DiseasesPathophysiological processes in multiple sclerosis: focus on nuclear factor erythroid-2-related factor 2 and emerging pathwaysCellular stress responses, the hormesis paradigm, and vitagenes: novel targets for therapeutic intervention in neurodegenerative disordersRegulation of APC development, immune response, and autoimmunity by Bach1/HO-1 pathway in miceMechanisms of oxidative damage in multiple sclerosis and neurodegenerative diseases: therapeutic modulation via fumaric acid estersEmerging roles of Nrf2 and phase II antioxidant enzymes in neuroprotectionNRF2-regulation in brain health and disease: implication of cerebral inflammationEffects of fumaric acids on cuprizone induced central nervous system de- and remyelination in the mouseCurrent and emerging therapies in multiple sclerosis: a systematic reviewUsing historical control information for the design and analysis of clinical trials with overdispersed count data.Alemtuzumab for the treatment of relapsing-remitting multiple sclerosis.Therapeutic strategies for relapsing-remitting multiple sclerosis: a special focus on reduction of grey matter damage as measured by brain atrophy.Subcortical brain segmentation of two dimensional T1-weighted data sets with FMRIB's Integrated Registration and Segmentation Tool (FIRST).Recent developments in multiple sclerosis therapeuticsVaricella-zoster virus infections in patients treated with fingolimod: risk assessment and consensus recommendations for management.The effectiveness of dimethyl fumarate monotherapy in the treatment of relapsing-remitting multiple sclerosis: a systematic review and meta-analysis.
P2860
Q22241472-DD557DBA-D564-4047-A74A-3F95690E9DC9Q22242305-8AFE6E38-DF56-4022-B60C-13EB973BA32AQ22252863-9CEF10F6-66F3-4D03-A642-BFFC182787EBQ22305854-4386CCA5-9FD2-45CA-ACA9-9E427F22F1C2Q24186433-5F1351F4-6CB8-4F15-9775-AE3E74B3CACEQ24187126-20C2318D-81D0-4D5A-A331-10C3A64C61A4Q24197602-2A157559-10AE-48DB-95EC-EF5BA865AA50Q24564715-DC6B2251-37AE-494F-91B4-FB519ADAA80DQ24597369-071764A3-AC4D-40AC-8EA1-54EE0F78F72DQ24626931-9C95B0AD-193A-4313-B0F4-F1F632935F51Q24648021-1E733ABD-FE79-4D9B-853C-C34147BDD0D6Q26738969-CCCFF714-EB8B-4F87-A1E7-1BBFACDEF78CQ26745562-2EFC868C-8059-419D-84D6-15F5000A4CDFQ26752859-0A40344A-2A7E-42DB-8652-30EFFB2BEFA2Q26785525-090C70D9-02FF-44BB-9E40-94E79AC74175Q26822611-4B53A8E5-5569-4D25-8A94-FC6D60D66661Q26823444-60DB4B88-8A40-4EF2-B6B9-BC058C46D879Q26826930-EB2915D1-867A-449E-B425-0673075CB36CQ26853672-BF2AFEE2-279F-4B92-B854-D9BA38861D98Q26998513-E874B824-0FAF-49F2-B2E6-FDDEE32D19EEQ27021147-BB8F10D9-5AA6-4B13-B215-AFF9EE15B261Q27023735-72E2D1A3-8FB3-4433-A52A-DFBBCE788019Q27346374-CCE8DFA2-6005-4DB4-9558-B1B77A965CF9Q28073849-F698FE03-B6FD-4DDB-A543-CB53D0854219Q28078742-16ED732B-69B5-4EC7-9241-AFE231D1382DQ28235168-3C003305-986E-42E6-88D7-F8927ED98BCDQ28384232-BF39E8E0-55BB-48CB-8520-73BC30CA1C97Q28388916-08020045-150E-48AE-A6B9-BCA6AD5214B8Q28389828-B343D4A9-3220-478D-B6E4-EA81E73B89A7Q28396785-DCFFBE85-E819-4033-8C94-C0C7ED2ECCF3Q28397785-C1A9A9C7-B5BE-4AD9-8976-4F56B91B2349Q28750219-1D86182C-2056-47D7-A0ED-B8191141633AQ29010983-3031E084-164B-4AED-979F-D7BAB0A3F4DAQ30636643-0282574B-709C-4F32-9816-63285DFAFE4AQ30808014-026BBCB8-72F8-4B38-B3D0-B48320D71475Q30869048-A2A5CB66-B1F3-4144-A258-68AC85BC0F03Q30885558-6E7E38E0-67AB-4268-B3C2-FF902AD07912Q30962193-6B261BBC-CCF7-464B-915A-3F16D2C5DA56Q33562804-F58E1A97-5C29-439A-A4A6-BB929B8EF5B5Q33621682-7A0806DB-A0E8-4C3A-8DA3-BBDC399AC5EA
P2860
Efficacy and safety of oral fumarate in patients with relapsing-remitting multiple sclerosis: a multicentre, randomised, double-blind, placebo-controlled phase IIb study.
description
2008 nî lūn-bûn
@nan
2008年の論文
@ja
2008年学术文章
@wuu
2008年学术文章
@zh
2008年学术文章
@zh-cn
2008年学术文章
@zh-hans
2008年学术文章
@zh-my
2008年学术文章
@zh-sg
2008年學術文章
@yue
2008年學術文章
@zh-hant
name
Efficacy and safety of oral fu ...... bo-controlled phase IIb study.
@en
Efficacy and safety of oral fu ...... bo-controlled phase IIb study.
@nl
type
label
Efficacy and safety of oral fu ...... bo-controlled phase IIb study.
@en
Efficacy and safety of oral fu ...... bo-controlled phase IIb study.
@nl
prefLabel
Efficacy and safety of oral fu ...... bo-controlled phase IIb study.
@en
Efficacy and safety of oral fu ...... bo-controlled phase IIb study.
@nl
P2093
P921
P1433
P1476
Efficacy and safety of oral fu ...... bo-controlled phase IIb study.
@en
P2093
Alfred W Sandrock
BG-12 Phase IIb Study Investigators
Chris H Polman
David G Macmanus
David H Miller
Eva Havrdova
Eva Meluzinova
Gilmore N O'Neill
Ivan Rektor
Katherine T Dawson
P304
P356
10.1016/S0140-6736(08)61619-0
P407
P577
2008-10-01T00:00:00Z